Drugs that contain Regorafenib
1. Drug name - STIVARGA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7351834 | BAYER HLTHCARE | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
Jun, 2022
(3 months ago) | |
| US8637553 | BAYER HLTHCARE | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
Feb, 2031
(8 years from now) | |
| US9957232 | BAYER HLTHCARE | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate |
Jul, 2032
(9 years from now) | |
| CN101257903A | BAYER HLTHCARE | Combination Therapy Comprising A Diaryl Urea Compound And A Pi3, Akt Kinase Or Mtor Inhibitors (Rapamycins) For Cancer Treatment |
Mar, 2011
(11 years ago) | |
| CN100522934C | BAYER HLTHCARE | Acardite As Raf Kinase Inhibitors With Omega-Carboxy Aryl Substituted |
Jan, 2020
(2 years ago) | |
| CN1721397A | BAYER HLTHCARE | For -Carboxy Aryl Substituted Diphenyl Urea As Raf Kinase Inhibitors |
Jan, 2020
(2 years ago) | |
| CN1219764C | BAYER HLTHCARE | For -Carboxy Aryl Substituted Diphenyl Urea As Raf Kinase Inhibitors |
Jan, 2020
(2 years ago) | |
| CN1341098A | BAYER HLTHCARE | For -Carboxy Aryl Substituted Diphenyl Urea As Raf Kinase Inhibitors |
Jan, 2020
(2 years ago) | |
| CN102816113B | BAYER HLTHCARE | Fluorin Generation [Omega]-Carboxylic Aryl Ureas For Treating And Preventing Symptoms And Disease |
Jul, 2024
(1 year, 9 months from now) | |
| CN1856469B | BAYER HLTHCARE | [Omega]-Carboxylic Aryl Phenylurea For The Treatment And Prevention Of Diseases And Disease Symptoms |
Jul, 2024
(1 year, 9 months from now) | |
| CN102816113A | BAYER HLTHCARE | Fluoro Omega-Carboxyaryl Diphenyl Urea For Treating And Preventing Disease And Disease Symptom |
Jul, 2024
(1 year, 9 months from now) | |
| CN1856469A | BAYER HLTHCARE | For The Treatment And Prevention Of Diseases And Disease Symptoms- Carboxylic Aryl Ureas |
Jul, 2024
(1 year, 9 months from now) | |
| CN101547903A | BAYER HLTHCARE | 4-[4-({[4-Chloro-3-(Trifluoromethyl)Phenyl)]Carbamoyl}Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate |
Sep, 2027
(4 years from now) | |
| CN101547903B | BAYER HLTHCARE | 4-[4-({[4-Chloro-3-(Trifluoromethyl)Phenyl)]Carbamoyl}Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate |
Sep, 2027
(4 years from now) | |
| IN215758B | BAYER HLTHCARE | Carboxyaryl Substituted Diphenyl Ureas |
Jan, 2020
(2 years ago) | |
| IN200100799P3 | BAYER HLTHCARE | Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
Jan, 2020
(2 years ago) | |
| IN200600402P1 | BAYER HLTHCARE | Fluoro Substituted Omega-Carboxyaryl Diphenyl Urea For The Treatment And Prevention Of Diseases And Conditions |
Jul, 2024
(1 year, 9 months from now) | |
| IN240207B | BAYER HLTHCARE | A Fluoro Substituted Omega-Carboxyaryl Diphenyl Urea Compound Or A Salt, An Isolated Stereoisomer Thereof |
Jul, 2024
(1 year, 9 months from now) | |
| EP1690853A1 | BAYER HLTHCARE | Use Of Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
Jan, 2020
(2 years ago) | |
| EP1690853B1 | BAYER HLTHCARE | Use Of Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
Jan, 2020
(2 years ago) | |
| EP2298311B1 | BAYER HLTHCARE | W-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors |
Jan, 2020
(2 years ago) | |
| EP1158985B1 | BAYER HLTHCARE | Omega-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors |
Jan, 2020
(2 years ago) | |
| EP1158985A1 | BAYER HLTHCARE | Omega-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors |
Jan, 2020
(2 years ago) | |
| EP1158985A4 | BAYER HLTHCARE | Omega-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors |
Jan, 2020
(2 years ago) | |
| EP2298311A1 | BAYER HLTHCARE | W-Carboxy Aryl Substituted Diphenyl Ureas As P38 Kinase Inhibitors |
Jan, 2020
(2 years ago) | |
| EP1140840B1 | BAYER HLTHCARE | -G(V)-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
Jul, 2021
(1 year, 2 months ago) | |
| EP1140840A1 | BAYER HLTHCARE | -G(V)-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
Jul, 2021
(1 year, 2 months ago) | |
| EP1140840A4 | BAYER HLTHCARE | -G(V)-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors |
Jul, 2021
(1 year, 2 months ago) | |
| EP1379507A1 | BAYER HLTHCARE | Heteroaryl Ureas Containing Nitrogen Hetero-Atoms As P38 Kinase Inhibitors |
Apr, 2022
(5 months ago) | |
| EP1379507B1 | BAYER HLTHCARE | Heteroaryl Ureas Containing Nitrogen Hetero-Atoms As P38 Kinase Inhibitors |
Apr, 2022
(5 months ago) | |
| EP2097381B1 | BAYER HLTHCARE | 4-[4-({[4-Chloro-3-(Trifluoromethyl)Phenyl)]Carbamoyl}Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate |
Sep, 2027
(4 years from now) | |
| EP2097381A1 | BAYER HLTHCARE | 4-[4-({[4-Chloro-3-(Trifluoromethyl)Phenyl)]Carbamoyl}Amino)-3-Fluorophenoxy]-N-Methylpyridine-2-Carboxamide Monohydrate |
Sep, 2027
(4 years from now) | |
| EP1663978B1 | BAYER HLTHCARE | Fluoro Substituted Omega-Carboxyaryl Diphenyl Urea For The Treatment And Prevention Of Diseases And Conditions |
Aug, 2028
(5 years from now) | |
| EP1663978A2 | BAYER HLTHCARE | Fluoro Substituted Omega-Carboxyaryl Diphenyl Urea For The Treatment And Prevention Of Diseases And Conditions |
Aug, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8680124 | BAYER HLTHCARE | Treatment of cancers with acquired resistance to kit inhibitors |
Jun, 2030
(7 years from now) | |
| US9458107 | BAYER HLTHCARE | Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate |
Apr, 2031
(8 years from now) | |
Treatment: Treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kinase inhibitor
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 40MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.